Interestingly, five studies included in the PFS analyses revealed significant or marginally significant HRs for an improved PFS for the overall PARPi-treated patients and PARPi-treated patients with BRCAm, BRCA wild type, HRD, or HRD without BRCAm.
← all excerpts
Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
1
—
—